FDA Approval of Dacomitinib for NSCLC - Is it the Gamechanger in the First-line Treatment?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

FDA Approval of Dacomitinib for NSCLC - Is it the Gamechanger in the First-line Treatment?

By Beacon Medical Interchange FEATURING Jack West

831 views

October 29, 2018

Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR ...
read more ↘ mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first-line treatment.
↖ read less

0 Comments